{"ticker": {"uuid": "f1dc8aec-487e-4ef2-a44d-e004cc6eb271", "symbol": "ENSC", "name": "Ensysce Biosciences Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Ensysce Biosciences (ENSC) price target decreased by 34.79% to 16.78", "summary": "", "url": "https://news.google.com/rss/articles/CBMiywJBVV95cUxONU1jNVVKR1doc1RhbGprb0c3eDZuX0VJd0RjZm1YRmJEd0F4dzFiYzcwUER3SDRlZlBtb3V5d1BzazQ1MmdMdktlMlVPYlNaVVYxSktZTFdjb01VN2VsMGpjZzdPdlUzUk9KOERPVndqdkJJLVZlTlZoQ0F5S09JYldDZ3Z2am5WQUR4Qk9ZLThjT1FzRWUzUHlEc2hBN1pSUXRjU2xyVkktdW9pX2VNX0hqbVpuN2l4WE0tT2Q0YlVWaU54M3VJOExjUnlZbUdMNGVaWlBXODd0dWdTTUtoX1ZBd2VyRFZyZFZHdTBDb3BURlozVnBNc1hMd2wxUjBDLUlsT2tzRVluRUtpQVNRWEp4WHJTZXh4RW1HYnZZdE5mazlheHU2cW1melc0cVBzcVowcW4xM0tqMkc5R2dSMmdsSGM4cmxoTFFn?oc=5", "source_name": "MSN", "published_at": "2026-07-18T11:36:16+00:00", "published_display": "18 Jul 2026 11:36", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ENSC News | ENSYSCE BIOSCIENCES INC (NASDAQ:ENSC)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiW0FVX3lxTE45OVJXTmtVOGhuZnlXdU82X2puNl9VajZ6NGFkM0JObFh1SXBQbW9uQV9ETEstNmx1SUR0X2V0dEVkRlhOM2U0dkRGV3ZVTUY0WDhIQU1MLUM3Y1k?oc=5", "source_name": "ChartMill", "published_at": "2026-07-18T00:00:02+00:00", "published_display": "18 Jul 2026 00:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Ensysce Biosciences COO Jeffrey Millard resigns effective July 10, 2026", "summary": "Jeffrey Millard, the Chief Operating Officer of Ensysce Biosciences, has resigned from his position, with the resignation becoming effective on July 10, 2026. The reasons for his departure and details about his replacement have not been disclosed. This information is based on an ", "url": "https://www.tradingview.com/news/tradingview:3652d5702e2fb:0-ensysce-biosciences-coo-jeffrey-millard-resigns-effective-july-10-2026/", "source_name": "TradingView", "published_at": "2026-07-16T03:41:09", "published_display": "16 Jul 2026 03:41", "sentiment": "negative", "sentiment_pct": 40, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ensysce Biosciences, Inc. Announces Resignation of Jeffrey Millard as Chief Operating Officer, Effective July 10, 2026", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5AFBVV95cUxPRWhrVnhlbzBOWHBsbktZVXVrUjZ1d3lYLU42M2NzTmNNdjNubkNSTC0wREdYcFlTTEY3YlVGdVBCYWJzUVY2ZGc0ZGxUekw0SXpDSGtJTVloQk1HUXMtQmg0eW9ZTERjclEtTF9ZT0l0SnNHdEpUY0FUem1FYU5zMWFlTWNUSXlxTW1QUVBnQ0U1QzR4WER0T3laYjVaVndrVVBBM2I3dEljVGRnNVB5LTlXaEhib210ajIxdVV4VU5TVF9zMXIyRlA3a0s3Z2plN3lvb08wWEwxdl9rZkdiTDc1RnI?oc=5", "source_name": "marketscreener.com", "published_at": "2026-07-15T20:16:00+00:00", "published_display": "15 Jul 2026 20:16", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "COO Jeffrey Millard exits Ensysce Biosciences (Nasdaq: ENSC) July 10", "summary": "Jeffrey Millard resigned from his position as Chief Operating Officer of Ensysce Biosciences (Nasdaq: ENSC), effective July 10, 2026. The company officially reported this material event via an 8-K filing on July 15, 2026. Ensysce Biosciences emphasizes its status as an emerging g", "url": "https://www.stocktitan.net/sec-filings/ENSC/8-k-ensysce-biosciences-inc-reports-material-event-09e4739ed27f.html", "source_name": "Stock Titan", "published_at": "2026-07-15T20:41:09", "published_display": "15 Jul 2026 20:41", "sentiment": "negative", "sentiment_pct": 36, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ensysce Biosciences Awarded $5.3 Million Installment in NIDA Funding Completing Multi-Year $15 Million Federal Grant", "summary": "Ensysce Biosciences has received the final $5.3 million installment of a $15.1 million federal grant from the National Institutes on Drug Abuse (NIDA). This funding will advance the development of PF614-MPAR, a novel opioid with oral overdose protection that has received FDA Brea", "url": "https://www.theglobeandmail.com/investing/markets/markets-news/ACCESS%20Newswire/3271477/ensysce-biosciences-awarded-5-3-million-installment-in-nida-funding-completing-multi-year-15-million-federal-grant/", "source_name": "The Globe and Mail", "published_at": "2026-07-15T04:41:09", "published_display": "15 Jul 2026 04:41", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ensysce receives $5.3M NIDA award for opioid overdose therapy", "summary": "Ensysce Biosciences, Inc. (ENSC) has been awarded $5.3 million from the National Institutes on Drug Abuse (NIDA) to advance its MPAR overdose-protection technology and lead agent PF614-MPAR, bringing total NIDA support to $15.1 million. This funding will help complete a clinical ", "url": "https://www.investing.com/news/company-news/ensysce-receives-53m-nida-award-for-opioid-overdose-therapy-93CH-4790685", "source_name": "Investing.com", "published_at": "2026-07-14T15:18:37", "published_display": "14 Jul 2026 15:18", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ensysce Biosciences Receives Final $5.3 Million NIDA Funding Installment for PF614-MPAR Development", "summary": "Ensysce Biosciences has received the final $5.3 million installment from a multi-year National Institute on Drug Abuse (NIDA) grant, bringing the total funding to $15.1 million. This funding will support the completion of the PF614-MPAR 102 clinical study and non-clinical work re", "url": "https://finance.yahoo.com/healthcare/articles/ensysce-biosciences-receives-final-5-144529754.html", "source_name": "Market source", "published_at": "2026-07-14T14:45:00", "published_display": "14 Jul 2026 14:45", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Federal funds back Ensysce opioid technology designed to limit overdose", "summary": "Ensysce Biosciences (NASDAQ: ENSC) has received a $5.3 million installment from the National Institute on Drug Abuse (NIDA), completing a multi-year $15.1 million federal grant for its MPAR\u00ae overdose-protection technology and lead candidate PF614-MPAR. This funding will support t", "url": "https://www.stocktitan.net/news/ENSC/ensysce-biosciences-awarded-5-3-million-installment-in-nida-funding-86hnfk9syhhv.html", "source_name": "Stock Titan", "published_at": "2026-07-14T11:39:46", "published_display": "14 Jul 2026 11:39", "sentiment": "positive", "sentiment_pct": 81, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T07:00:00+00:00", "published_display": "13 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Postoperative Pain - Pipeline Insight, 2026 Now Available; Comprehensive Profiles of 40+ Key Players Including Ensysce Biosciences and Allay Therapeutics", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/postoperative-pain-pipeline-insight-2026-144100744.html", "source_name": "GlobeNewswire", "published_at": "2026-07-09T14:41:00+00:00", "published_display": "09 Jul 2026 14:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ensysce Biosciences (ENSC) Edges Higher: Key Support Holds as Volume Picks Up - Profitability Factor", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxQT01rYWFONHNBdldXRzdyMU44SUFQaFlzbnh4NDVoM21ubGMyRFdVajNUN2ptMTdlcXotZnRCbTZvaXFBc2lwRURnM29iNWNOUlNaRlNfMFY4eHp4VGFWNHhRQlpKbGRBODZ3czBLbjdPa1ZhQ2ZRLUVoNXVPb2g4TzhTRm8yWGwxelpYb2d4VHMxRjRxMEc0RHR1WUxNbGs1bVp5ZEJ3T1p0bTUyOGJVV1RtWFI3akU?oc=5", "source_name": "dars.gov.et", "published_at": "2026-07-06T07:00:00+00:00", "published_display": "06 Jul 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ensysce Biosciences, Inc. Financial Disclosures & SEC Filings", "summary": "This page provides access to Ensysce Biosciences, Inc.'s SEC filings and other financial documents, including Forms 10-K, 10-Q, and 8-K. The listed documents detail the company's earnings reports, corporate events, and investor presentations from 2017 to 2026, highlighting clinic", "url": "https://www.tradingview.com/symbols/BOATS-ENSC/documents/", "source_name": "TradingView", "published_at": "2026-07-05T06:10:36", "published_display": "05 Jul 2026 06:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Ensysce Biosciences, Inc. \u2013 NASDAQ:ENSC", "summary": "This article provides a brief financial overview of Ensysce Biosciences, Inc. (NASDAQ: ENSC), specifically focusing on its forward price-to-sales ratio. It's a snapshot from TradingView, indicating the stock's status and offering links to more detailed financial data and communit", "url": "https://www.tradingview.com/symbols/NASDAQ-ENSC/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-30T06:10:09", "published_display": "30 Jun 2026 06:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[EFFECT] Ensysce Biosciences, Inc. SEC Filing", "summary": "Ensysce Biosciences, Inc. (ENSC) announced that its S-3 Shelf Registration Statement has become effective as of June 26, 2026, at 4:30 P.M. The filing was accepted by the SEC EDGAR on June 29, 2026, at 06:05 AM. This notice indicates that the company now has a registration statem", "url": "https://www.stocktitan.net/sec-filings/ENSC/effect-ensysce-biosciences-inc-sec-filing-b7d8d77ec5ca.html", "source_name": "Stock Titan", "published_at": "2026-06-29T10:04:53", "published_display": "29 Jun 2026 10:04", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Ensysce Biosciences, Inc. \u2013 NASDAQ:ENSC", "summary": "This article provides financial data for Ensysce Biosciences, Inc. (NASDAQ: ENSC), specifically focusing on its price-to-book forward ratio. The content is primarily a data presentation page from TradingView, including market information and links to various financial tools and c", "url": "https://www.tradingview.com/symbols/NASDAQ-ENSC/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-29T03:40:52", "published_display": "29 Jun 2026 03:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ensysce initiates final stage of opioid overdose protection study", "summary": "Ensysce Biosciences (NASDAQ:ENSC) has begun the final stage of its PF614-MPAR-102 clinical study, evaluating its MPAR technology designed to prevent oral opioid overdose. Despite the stock's significant decline over the past year and a warning from Nasdaq regarding minimum stockh", "url": "https://www.investing.com/news/company-news/ensysce-initiates-final-stage-of-opioid-overdose-protection-study-93CH-4762695", "source_name": "Investing.com", "published_at": "2026-06-26T22:10:56", "published_display": "26 Jun 2026 22:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ensysce Biosciences Enrolls First Patient in Final Phase of Oral Overdose Study", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/ensysce-biosciences-enrolls-first-patient-124725744.html", "source_name": "MT Newswires", "published_at": "2026-06-26T12:47:25+00:00", "published_display": "26 Jun 2026 12:47", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ensysce initiates final stage of opioid overdose protection study By Investing.com", "summary": "Ensysce Biosciences (NASDAQ: ENSC) has initiated the final stage of its PF614-MPAR-102 clinical study, evaluating its Multi-Pill Abuse Resistance (MPAR) technology designed to prevent opioid overdose. Despite a significant stock decline and cash burn, the company's technology has", "url": "https://ng.investing.com/news/stock-market-news/ensysce-initiates-final-stage-of-opioid-overdose-protection-study-93CH-2575857", "source_name": "Investing.com Nigeria", "published_at": "2026-06-26T13:14:00", "published_display": "26 Jun 2026 13:14", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ensysce Biosciences enrolls first patient in final stage of PF614-MPAR-102 study", "summary": "Ensysce Biosciences has enrolled the first patient in the final stage of its PF614-MPAR-102 clinical study. This trial is evaluating PF614-MPAR, an opioid candidate with MPAR\u00ae overdose-protection technology, for the treatment of severe pain. The study is supported by the National", "url": "https://grafa.com/news/united-states/ensysce-biosciences-first-patient-pf614-mpar-102-final-stage", "source_name": "grafa.com", "published_at": "2026-06-26T12:45:00", "published_display": "26 Jun 2026 12:45", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ensysce Biosciences(ENSC) Stock Options Chain | Quotes & News", "summary": "This document appears to be a stub or an incomplete article related to Ensysce Biosciences (ENSC) stock options chain, quotes, and news. Currently, it contains no substantive content beyond its title.", "url": "https://www.moomoo.com/stock/ENSC-US/options-chain?chain_id=Name1K9-3FXPhg.1l07fo0&global_content=%7B%22promote_id%22%3A11927,%22sub_promote_id%22%3A45,%22f%22%3A%22www.moomoo.com%2Fau%2Flearn%2Fdetail-best-uranium-stocks-asx-117469-240973124%22%7D", "source_name": "Moomoo", "published_at": "2026-06-26T12:39:11", "published_display": "26 Jun 2026 12:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ensysce Biosciences Enrolls First Patient in Final Phase of PF614-MPAR-102 Clinical Study", "summary": "Ensysce Biosciences has enrolled the first patient in the final stage of its PF614-MPAR-102 clinical study for its overdose-protection opioid candidate, PF614-MPAR. This candidate utilizes MPAR\u00ae technology designed to prevent oral overdose while providing therapeutic opioid expos", "url": "https://www.stocktitan.net/news/ENSC/ensysce-biosciences-enrolls-first-patient-in-final-phase-of-pf614-8sesj3br8p8p.html", "source_name": "Stock Titan", "published_at": "2026-06-26T12:10:34", "published_display": "26 Jun 2026 12:10", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ensysce starts final PF614-MPAR study stage for overdose-protection opioid", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxQRHVZU1JBNzVSeHZfejJnRkE0SWZrRVp2U3NxMW5TTVg0M2xaR2NTa2lsWGZaMHkzNzd1SDZla1UzdXFJa0k5TnBhS0paSHRMSkpvSkF5NHE2M0FrTEhsV3k1NjM2d1liWlRGV1ktUkRYUW83ZWFfdUtwcVN1VHFmalpUQmVRU0NLc093NnlZajVTbWFjODRUYUFHQml0a1otVjhwT0VvZURRMi1JX2FPVjNxMUtkd01LTU5lXw?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-26T07:00:00+00:00", "published_display": "26 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ensysce Biosciences, Inc. Actuals & Estimates (NASDAQ:ENSC)", "summary": "This article provides an overview of Ensysce Biosciences, Inc. (ENSC) stock, including its current price, historical performance, analyst forecasts, and financial data. It covers frequently asked questions about ENSC, such as its market capitalization, earnings reports, revenue, ", "url": "https://www.tradingview.com/symbols/NASDAQ-ENSC/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-25T22:10:09", "published_display": "25 Jun 2026 22:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ensysce Biosciences Inc (ENSC) Valuation: PE, PB & Fair Value Analysis", "summary": "This article provides a valuation analysis of Ensysce Biosciences Inc (ENSC), highlighting its current valuation score, P/E ratio, and industry ranking. As of June 26, 2026, the company holds a valuation score of 9.51, placing it 27th out of 387 in the Biotechnology & Medical Res", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-ensc/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-22T23:10:42", "published_display": "22 Jun 2026 23:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ensysce Biosciences Inc (ENSC) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "This article provides an overview of Ensysce Biosciences Inc (ENSC) stock information, including its dividend history and stock split events. It indicates that the company has distributed no dividends over the past five years but has undergone several merger-related stock splits ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-ensc/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-19T01:49:01", "published_display": "19 Jun 2026 01:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ensysce Biosciences Inc (ENSC) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "This article from TradingKey provides a revenue breakdown for Ensysce Biosciences Inc (ENSC). It states that relevant data regarding the company's business segments, regional revenue, and profit contribution have not yet been disclosed by the company. The page also presents basic", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-ensc/revenue", "source_name": "TradingKey", "published_at": "2026-06-19T00:49:01", "published_display": "19 Jun 2026 00:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ensysce Biosciences Inc (ENSC) Financial Health: Profitability & Balance Sheet Analysis", "summary": "Ensysce Biosciences Inc (ENSC) has a weak financial health score of 7.50 out of 388 in the Biotechnology & Medical Research industry, with average operating efficiency. The company's latest quarterly revenue decreased by 27.18% year-over-year, and its net profit saw an 82.80% yea", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-ensc/financial-health", "source_name": "TradingKey", "published_at": "2026-06-18T11:09:32", "published_display": "18 Jun 2026 11:09", "sentiment": "negative", "sentiment_pct": 30, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ensysce Biosciences Inc (ENSC) Institutional Confidence", "summary": "This article provides an \"Institutional Confidence\" score for Ensysce Biosciences Inc (ENSC) as of June 17, 2026, which remains unchanged at 3.00. It details the shareholdings and activity of several institutional investors, including Adage Capital Management, L.P. and DRW Securi", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-ensc/sentiment", "source_name": "TradingKey", "published_at": "2026-06-18T10:09:32", "published_display": "18 Jun 2026 10:09", "sentiment": "positive", "sentiment_pct": 69, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ensysce Biosciences Inc (ENSC) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "This article provides a technical analysis of Ensysce Biosciences Inc (ENSC), detailing its current price momentum score, support and resistance levels, and insights from various technical indicators. It notes ENSC's stock is trading between resistance at $0.32 and support at $0.", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-ensc/technical", "source_name": "TradingKey", "published_at": "2026-06-18T10:09:32", "published_display": "18 Jun 2026 10:09", "sentiment": "negative", "sentiment_pct": 38, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ENSC Stock Chart | ENSYSCE BIOSCIENCES INC (NASDAQ:ENSC)", "summary": "This page from ChartMill.com provides a stock chart and current price information for ENSYSCE BIOSCIENCES INC (NASDAQ:ENSC). It shows the stock's performance, including daily, weekly, and monthly views, along with technical and fundamental analysis options. The current stock pric", "url": "https://www.chartmill.com/stock/quote/ENSC/stock-chart", "source_name": "ChartMill", "published_at": "2026-06-06T02:09:24", "published_display": "06 Jun 2026 02:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ENSC - Ensysce Biosciences Inc Stock Price and Quote", "summary": "This page provides a detailed overview of Ensysce Biosciences Inc (ENSC) stock, including its latest trading information, financial metrics, and a comprehensive list of recent news and press releases. It highlights the company's focus on developing tamper-proof opioids with overd", "url": "https://finviz.com/stock?t=ENSC", "source_name": "Finviz", "published_at": "2026-06-05T01:09:41", "published_display": "05 Jun 2026 01:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ensysce Biosciences Files for Sale of 1.3 Million Shares", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/ensysce-biosciences-files-sale-1-210241213.html", "source_name": "MT Newswires", "published_at": "2026-06-04T21:02:41+00:00", "published_display": "04 Jun 2026 21:02", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ensysce Biosciences (NASDAQ: ENSC) registers up to 1.3M shares for resale", "summary": "Ensysce Biosciences (NASDAQ: ENSC) has filed an S-3 registration statement to register up to 1.3 million shares of common stock for resale. These shares are primarily issuable to a manufacturing counterparty and through a separate agreement, with proceeds from resales going to th", "url": "https://www.stocktitan.net/sec-filings/ENSC/s-3-ensysce-biosciences-inc-shelf-registration-statement-fbc343994331.html", "source_name": "Stock Titan", "published_at": "2026-06-04T20:38:40", "published_display": "04 Jun 2026 20:38", "sentiment": "negative", "sentiment_pct": 37, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ensysce Biosciences receives Nasdaq notice for non-compliance with equity rule", "summary": "Ensysce Biosciences (NASDAQ: ENSC) has received a notice from Nasdaq for non-compliance with the minimum stockholders' equity requirement, falling below the $2.5 million threshold as of March 31, 2026. The company must submit a plan to regain compliance within 45 days to avoid de", "url": "https://www.investing.com/news/sec-filings/ensysce-biosciences-receives-nasdaq-notice-for-noncompliance-with-equity-rule-93CH-4707811", "source_name": "Investing.com", "published_at": "2026-05-22T23:39:52", "published_display": "22 May 2026 23:39", "sentiment": "negative", "sentiment_pct": 20, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ensysce Biosciences (NASDAQ: ENSC) warned on Nasdaq equity listing rule", "summary": "Ensysce Biosciences Inc. (NASDAQ: ENSC) has received a notice from Nasdaq regarding its non-compliance with the minimum $2.5 million stockholders\u2019 equity requirement as of March 31, 2026. The company has 45 days, until July 6, 2026, to submit a plan to regain compliance, with a p", "url": "https://www.stocktitan.net/sec-filings/ENSC/8-k-ensysce-biosciences-inc-reports-material-event-c5cdb7224555.html", "source_name": "Stock Titan", "published_at": "2026-05-22T20:39:52", "published_display": "22 May 2026 20:39", "sentiment": "negative", "sentiment_pct": 19, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ensysce Biosciences Reports First Quarter 2026 Financial Results", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/ensysce-biosciences-reports-first-quarter-201500674.html", "source_name": "ACCESS Newswire", "published_at": "2026-05-15T20:15:00+00:00", "published_display": "15 May 2026 20:15", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Ensysce CEO outlines abuse-resistant opioid approach in Amsterdam", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxQeTN6dXYzUFJLSUQ3X1JTdzdRbFFQUmNIMEpCNzhYeHgtczVRLUpzdlc0eVlYLUdRYkxBUXRmWXJEakM2RUZ5X0tXMkF0dnF5ZUR6QWxsc3pFdk5oV2FXcnBxZ0F6SEFobmFhY1EwanE4cHR6cHQ4ZjZBS0hJRmROWWNialRLZmwxcWVka0doZTJLNnpBQ0U5c1ZEV2IxMDNBY0t3Q1pVUjlFbjNTWEV0RGxOcVc?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-08T07:00:00+00:00", "published_display": "08 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "CEO takes live questions on Ensysce PF614 pain-drug plans", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxPbnRVX3pjX2NOLXFTdFVzVkM1Zl82Z2VVdmxEV1FsT0JUMTRVUTBEdTE1VUJ3TU9fSlQwa1Rfb1pOZm1uOVZXa3d1dU5YekMxVWxYbXFFS01ncG11U0FydzBjU0ZGbHY1S3JPRlJ2cjlvZm9RTF9JWWdXMXg0ZHNON2c4N3o1cEdiTzJIcnlObHdxMlhSOWNBbkhxczNTMTI4bnVQTFR4SEZ6ZW1teWdmTmNuZ0RIMVlN?oc=5", "source_name": "Stock Titan", "published_at": "2026-03-04T08:00:00+00:00", "published_display": "04 Mar 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Opioid safety drug developer Ensysce explores deals, possible asset sales", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxPNW9ZTzYwck1aTndlYjJYbEctQkdDRXowblhRUnU1S0piNmFzQ3hmSldkRExtNGNSdlB3bF9qUXlIUnh0RmRsc0NhbUtfWkotbURZY2Jxb1FKN1plNFZvT3U1VHBzNVA1NlFFaHZxS25zSmJjMld1WWtjaDVFRnItNnFESVJWMDZiTVVEbEF4RkFsRFlYa2NzNXU3eWttdzg4TXkxakZqX0FyTHV1dDFESTB4c1RyT2pTMWhHQg?oc=5", "source_name": "Stock Titan", "published_at": "2026-02-25T08:00:00+00:00", "published_display": "25 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Should You Buy Ensysce Biosciences After Share Sale?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiggFBVV95cUxQcFdydHZiQXhMX1Y3aElvVGxRcHNEa3FpNGhpQWJTNC1FTzRVTjhaYUtrcXo5S2lmOTJRWGhQbVNCTk9NU2I4RDRzckl2d3dLQzNEZEcwRFM4TVI5cnVsUS1pUnl0bWtGVmdVcUY2TTlvQXF6aDZ5R2JMVVNyV3kwOGNB?oc=5", "source_name": "StocksToTrade", "published_at": "2025-12-09T08:00:00+00:00", "published_display": "09 Dec 2025 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Ensysce Biosciences a Hidden Gem?", "summary": "", "url": "https://news.google.com/rss/articles/CBMihgFBVV95cUxNMG5pUFM3a0ZlSEk5QWVFaktVWTd1NXpXQjhTazl5RzA0VHl2SGU1VEpScGRjb2NuSUFMTXdjckl2M2ZMdW1uSEhyaElpRVJDVmVET08xekprb21ZbHVYN0Z2VDhJQlotU3I1anJmRFd0WWlzQ2tLUVByMzNjdU56RHpiRzIxZw?oc=5", "source_name": "timothysykes.com", "published_at": "2025-12-09T08:00:00+00:00", "published_display": "09 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ensysce Biosciences Stock Rises On Positive Data From Opioid Overdose Protection Study: Retail\u2019s Thrilled", "summary": "", "url": "https://news.google.com/rss/articles/CBMi3AFBVV95cUxOcXJyVmIxNEsyR0ZuTjdvYmRHWFhLQkJnZllQQjdlOHR0OFgyNmJuTWJ5SzZFZjdfSnVxcFpfTGkxdXNmaGNqMURnTjhFSWtiNTJZc0drOVp2LXpqLXJfcjRzdVBwUTk1Qjl3dThrZTFxT2hLeVVVT29ETUJnZTJQTklTbkRxZ2NXdFFrN1pKbDBkenA2ZjlueVBFWmpxZzJOUnI2ekY3eVc2c3pYdXUwaE90YjI2MWtEMHB1S2ZqUlJhbDRCMEIycTJDa0JlWnZjZ0wzRFBRd1BhdWxm?oc=5", "source_name": "Stocktwits", "published_at": "2025-04-15T07:00:00+00:00", "published_display": "15 Apr 2025 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ensysce Biosciences Stock Price Forecast. Should You Buy ENSC?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiSEFVX3lxTE1FZWo2N3QxWXRETHA0SFhYMXA3R1JYT1A1OERMbC1BNk5WWnl2UVF3VEdOTnNBVU1aMDdVdVBYaHp1VHZsSExLRA?oc=5", "source_name": "StockInvest.us", "published_at": "2021-07-16T13:58:03+00:00", "published_display": "16 Jul 2021 13:58", "sentiment": "positive", "sentiment_pct": 66, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ensysce Biosciences (ENSC) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiWkFVX3lxTE9ueEhTdmx2aGpyRms0X0NJZDRlTG50Y3UzQURZYk80amtMSlRpSkdnUFBxbkRsaHhHS3ZybU5Cd0ZVbHNYTnlKSjdVbGxNOHFPSzlqN0hXV2Npdw?oc=5", "source_name": "MarketBeat", "published_at": "2021-07-06T10:17:51+00:00", "published_display": "06 Jul 2021 10:17", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Ensysce Biosciences (ENSC) price target decreased by 34.79% to 16.78", "summary": "", "url": "https://news.google.com/rss/articles/CBMiywJBVV95cUxONU1jNVVKR1doc1RhbGprb0c3eDZuX0VJd0RjZm1YRmJEd0F4dzFiYzcwUER3SDRlZlBtb3V5d1BzazQ1MmdMdktlMlVPYlNaVVYxSktZTFdjb01VN2VsMGpjZzdPdlUzUk9KOERPVndqdkJJLVZlTlZoQ0F5S09JYldDZ3Z2am5WQUR4Qk9ZLThjT1FzRWUzUHlEc2hBN1pSUXRjU2xyVkktdW9pX2VNX0hqbVpuN2l4WE0tT2Q0YlVWaU54M3VJOExjUnlZbUdMNGVaWlBXODd0dWdTTUtoX1ZBd2VyRFZyZFZHdTBDb3BURlozVnBNc1hMd2wxUjBDLUlsT2tzRVluRUtpQVNRWEp4WHJTZXh4RW1HYnZZdE5mazlheHU2cW1melc0cVBzcVowcW4xM0tqMkc5R2dSMmdsSGM4cmxoTFFn?oc=5", "source_name": "MSN", "published_at": "2026-07-18T11:36:16+00:00", "published_display": "18 Jul 2026 11:36", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ENSC News | ENSYSCE BIOSCIENCES INC (NASDAQ:ENSC)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiW0FVX3lxTE45OVJXTmtVOGhuZnlXdU82X2puNl9VajZ6NGFkM0JObFh1SXBQbW9uQV9ETEstNmx1SUR0X2V0dEVkRlhOM2U0dkRGV3ZVTUY0WDhIQU1MLUM3Y1k?oc=5", "source_name": "ChartMill", "published_at": "2026-07-18T00:00:02+00:00", "published_display": "18 Jul 2026 00:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ensysce Biosciences COO Jeffrey Millard resigns effective July 10, 2026", "summary": "Jeffrey Millard, the Chief Operating Officer of Ensysce Biosciences, has resigned from his position, with the resignation becoming effective on July 10, 2026. The reasons for his departure and details about his replacement have not been disclosed. This information is based on an ", "url": "https://www.tradingview.com/news/tradingview:3652d5702e2fb:0-ensysce-biosciences-coo-jeffrey-millard-resigns-effective-july-10-2026/", "source_name": "TradingView", "published_at": "2026-07-16T03:41:09", "published_display": "16 Jul 2026 03:41", "sentiment": "negative", "sentiment_pct": 40, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ensysce Biosciences, Inc. Announces Resignation of Jeffrey Millard as Chief Operating Officer, Effective July 10, 2026", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5AFBVV95cUxPRWhrVnhlbzBOWHBsbktZVXVrUjZ1d3lYLU42M2NzTmNNdjNubkNSTC0wREdYcFlTTEY3YlVGdVBCYWJzUVY2ZGc0ZGxUekw0SXpDSGtJTVloQk1HUXMtQmg0eW9ZTERjclEtTF9ZT0l0SnNHdEpUY0FUem1FYU5zMWFlTWNUSXlxTW1QUVBnQ0U1QzR4WER0T3laYjVaVndrVVBBM2I3dEljVGRnNVB5LTlXaEhib210ajIxdVV4VU5TVF9zMXIyRlA3a0s3Z2plN3lvb08wWEwxdl9rZkdiTDc1RnI?oc=5", "source_name": "marketscreener.com", "published_at": "2026-07-15T20:16:00+00:00", "published_display": "15 Jul 2026 20:16", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "COO Jeffrey Millard exits Ensysce Biosciences (Nasdaq: ENSC) July 10", "summary": "Jeffrey Millard resigned from his position as Chief Operating Officer of Ensysce Biosciences (Nasdaq: ENSC), effective July 10, 2026. The company officially reported this material event via an 8-K filing on July 15, 2026. Ensysce Biosciences emphasizes its status as an emerging g", "url": "https://www.stocktitan.net/sec-filings/ENSC/8-k-ensysce-biosciences-inc-reports-material-event-09e4739ed27f.html", "source_name": "Stock Titan", "published_at": "2026-07-15T20:41:09", "published_display": "15 Jul 2026 20:41", "sentiment": "negative", "sentiment_pct": 36, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ensysce Biosciences Awarded $5.3 Million Installment in NIDA Funding Completing Multi-Year $15 Million Federal Grant", "summary": "Ensysce Biosciences has received the final $5.3 million installment of a $15.1 million federal grant from the National Institutes on Drug Abuse (NIDA). This funding will advance the development of PF614-MPAR, a novel opioid with oral overdose protection that has received FDA Brea", "url": "https://www.theglobeandmail.com/investing/markets/markets-news/ACCESS%20Newswire/3271477/ensysce-biosciences-awarded-5-3-million-installment-in-nida-funding-completing-multi-year-15-million-federal-grant/", "source_name": "The Globe and Mail", "published_at": "2026-07-15T04:41:09", "published_display": "15 Jul 2026 04:41", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ensysce receives $5.3M NIDA award for opioid overdose therapy", "summary": "Ensysce Biosciences, Inc. (ENSC) has been awarded $5.3 million from the National Institutes on Drug Abuse (NIDA) to advance its MPAR overdose-protection technology and lead agent PF614-MPAR, bringing total NIDA support to $15.1 million. This funding will help complete a clinical ", "url": "https://www.investing.com/news/company-news/ensysce-receives-53m-nida-award-for-opioid-overdose-therapy-93CH-4790685", "source_name": "Investing.com", "published_at": "2026-07-14T15:18:37", "published_display": "14 Jul 2026 15:18", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ensysce Biosciences Receives Final $5.3 Million NIDA Funding Installment for PF614-MPAR Development", "summary": "Ensysce Biosciences has received the final $5.3 million installment from a multi-year National Institute on Drug Abuse (NIDA) grant, bringing the total funding to $15.1 million. This funding will support the completion of the PF614-MPAR 102 clinical study and non-clinical work re", "url": "https://finance.yahoo.com/healthcare/articles/ensysce-biosciences-receives-final-5-144529754.html", "source_name": "Market source", "published_at": "2026-07-14T14:45:00", "published_display": "14 Jul 2026 14:45", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Federal funds back Ensysce opioid technology designed to limit overdose", "summary": "Ensysce Biosciences (NASDAQ: ENSC) has received a $5.3 million installment from the National Institute on Drug Abuse (NIDA), completing a multi-year $15.1 million federal grant for its MPAR\u00ae overdose-protection technology and lead candidate PF614-MPAR. This funding will support t", "url": "https://www.stocktitan.net/news/ENSC/ensysce-biosciences-awarded-5-3-million-installment-in-nida-funding-86hnfk9syhhv.html", "source_name": "Stock Titan", "published_at": "2026-07-14T11:39:46", "published_display": "14 Jul 2026 11:39", "sentiment": "positive", "sentiment_pct": 81, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Postoperative Pain - Pipeline Insight, 2026 Now Available; Comprehensive Profiles of 40+ Key Players Including Ensysce Biosciences and Allay Therapeutics", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/postoperative-pain-pipeline-insight-2026-144100744.html", "source_name": "GlobeNewswire", "published_at": "2026-07-09T14:41:00+00:00", "published_display": "09 Jul 2026 14:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ensysce Biosciences (ENSC) Edges Higher: Key Support Holds as Volume Picks Up - Profitability Factor", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxQT01rYWFONHNBdldXRzdyMU44SUFQaFlzbnh4NDVoM21ubGMyRFdVajNUN2ptMTdlcXotZnRCbTZvaXFBc2lwRURnM29iNWNOUlNaRlNfMFY4eHp4VGFWNHhRQlpKbGRBODZ3czBLbjdPa1ZhQ2ZRLUVoNXVPb2g4TzhTRm8yWGwxelpYb2d4VHMxRjRxMEc0RHR1WUxNbGs1bVp5ZEJ3T1p0bTUyOGJVV1RtWFI3akU?oc=5", "source_name": "dars.gov.et", "published_at": "2026-07-06T07:00:00+00:00", "published_display": "06 Jul 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ensysce Biosciences, Inc. Financial Disclosures & SEC Filings", "summary": "This page provides access to Ensysce Biosciences, Inc.'s SEC filings and other financial documents, including Forms 10-K, 10-Q, and 8-K. The listed documents detail the company's earnings reports, corporate events, and investor presentations from 2017 to 2026, highlighting clinic", "url": "https://www.tradingview.com/symbols/BOATS-ENSC/documents/", "source_name": "TradingView", "published_at": "2026-07-05T06:10:36", "published_display": "05 Jul 2026 06:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Ensysce Biosciences, Inc. \u2013 NASDAQ:ENSC", "summary": "This article provides a brief financial overview of Ensysce Biosciences, Inc. (NASDAQ: ENSC), specifically focusing on its forward price-to-sales ratio. It's a snapshot from TradingView, indicating the stock's status and offering links to more detailed financial data and communit", "url": "https://www.tradingview.com/symbols/NASDAQ-ENSC/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-30T06:10:09", "published_display": "30 Jun 2026 06:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[EFFECT] Ensysce Biosciences, Inc. SEC Filing", "summary": "Ensysce Biosciences, Inc. (ENSC) announced that its S-3 Shelf Registration Statement has become effective as of June 26, 2026, at 4:30 P.M. The filing was accepted by the SEC EDGAR on June 29, 2026, at 06:05 AM. This notice indicates that the company now has a registration statem", "url": "https://www.stocktitan.net/sec-filings/ENSC/effect-ensysce-biosciences-inc-sec-filing-b7d8d77ec5ca.html", "source_name": "Stock Titan", "published_at": "2026-06-29T10:04:53", "published_display": "29 Jun 2026 10:04", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Ensysce Biosciences, Inc. \u2013 NASDAQ:ENSC", "summary": "This article provides financial data for Ensysce Biosciences, Inc. (NASDAQ: ENSC), specifically focusing on its price-to-book forward ratio. The content is primarily a data presentation page from TradingView, including market information and links to various financial tools and c", "url": "https://www.tradingview.com/symbols/NASDAQ-ENSC/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-29T03:40:52", "published_display": "29 Jun 2026 03:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ensysce initiates final stage of opioid overdose protection study", "summary": "Ensysce Biosciences (NASDAQ:ENSC) has begun the final stage of its PF614-MPAR-102 clinical study, evaluating its MPAR technology designed to prevent oral opioid overdose. Despite the stock's significant decline over the past year and a warning from Nasdaq regarding minimum stockh", "url": "https://www.investing.com/news/company-news/ensysce-initiates-final-stage-of-opioid-overdose-protection-study-93CH-4762695", "source_name": "Investing.com", "published_at": "2026-06-26T22:10:56", "published_display": "26 Jun 2026 22:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ensysce Biosciences Enrolls First Patient in Final Phase of Oral Overdose Study", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/ensysce-biosciences-enrolls-first-patient-124725744.html", "source_name": "MT Newswires", "published_at": "2026-06-26T12:47:25+00:00", "published_display": "26 Jun 2026 12:47", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ensysce initiates final stage of opioid overdose protection study By Investing.com", "summary": "Ensysce Biosciences (NASDAQ: ENSC) has initiated the final stage of its PF614-MPAR-102 clinical study, evaluating its Multi-Pill Abuse Resistance (MPAR) technology designed to prevent opioid overdose. Despite a significant stock decline and cash burn, the company's technology has", "url": "https://ng.investing.com/news/stock-market-news/ensysce-initiates-final-stage-of-opioid-overdose-protection-study-93CH-2575857", "source_name": "Investing.com Nigeria", "published_at": "2026-06-26T13:14:00", "published_display": "26 Jun 2026 13:14", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ensysce Biosciences enrolls first patient in final stage of PF614-MPAR-102 study", "summary": "Ensysce Biosciences has enrolled the first patient in the final stage of its PF614-MPAR-102 clinical study. This trial is evaluating PF614-MPAR, an opioid candidate with MPAR\u00ae overdose-protection technology, for the treatment of severe pain. The study is supported by the National", "url": "https://grafa.com/news/united-states/ensysce-biosciences-first-patient-pf614-mpar-102-final-stage", "source_name": "grafa.com", "published_at": "2026-06-26T12:45:00", "published_display": "26 Jun 2026 12:45", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ensysce Biosciences(ENSC) Stock Options Chain | Quotes & News", "summary": "This document appears to be a stub or an incomplete article related to Ensysce Biosciences (ENSC) stock options chain, quotes, and news. Currently, it contains no substantive content beyond its title.", "url": "https://www.moomoo.com/stock/ENSC-US/options-chain?chain_id=Name1K9-3FXPhg.1l07fo0&global_content=%7B%22promote_id%22%3A11927,%22sub_promote_id%22%3A45,%22f%22%3A%22www.moomoo.com%2Fau%2Flearn%2Fdetail-best-uranium-stocks-asx-117469-240973124%22%7D", "source_name": "Moomoo", "published_at": "2026-06-26T12:39:11", "published_display": "26 Jun 2026 12:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ensysce Biosciences Enrolls First Patient in Final Phase of PF614-MPAR-102 Clinical Study", "summary": "Ensysce Biosciences has enrolled the first patient in the final stage of its PF614-MPAR-102 clinical study for its overdose-protection opioid candidate, PF614-MPAR. This candidate utilizes MPAR\u00ae technology designed to prevent oral overdose while providing therapeutic opioid expos", "url": "https://www.stocktitan.net/news/ENSC/ensysce-biosciences-enrolls-first-patient-in-final-phase-of-pf614-8sesj3br8p8p.html", "source_name": "Stock Titan", "published_at": "2026-06-26T12:10:34", "published_display": "26 Jun 2026 12:10", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ensysce starts final PF614-MPAR study stage for overdose-protection opioid", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxQRHVZU1JBNzVSeHZfejJnRkE0SWZrRVp2U3NxMW5TTVg0M2xaR2NTa2lsWGZaMHkzNzd1SDZla1UzdXFJa0k5TnBhS0paSHRMSkpvSkF5NHE2M0FrTEhsV3k1NjM2d1liWlRGV1ktUkRYUW83ZWFfdUtwcVN1VHFmalpUQmVRU0NLc093NnlZajVTbWFjODRUYUFHQml0a1otVjhwT0VvZURRMi1JX2FPVjNxMUtkd01LTU5lXw?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-26T07:00:00+00:00", "published_display": "26 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ensysce Biosciences, Inc. Actuals & Estimates (NASDAQ:ENSC)", "summary": "This article provides an overview of Ensysce Biosciences, Inc. (ENSC) stock, including its current price, historical performance, analyst forecasts, and financial data. It covers frequently asked questions about ENSC, such as its market capitalization, earnings reports, revenue, ", "url": "https://www.tradingview.com/symbols/NASDAQ-ENSC/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-25T22:10:09", "published_display": "25 Jun 2026 22:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ensysce Biosciences Inc (ENSC) Valuation: PE, PB & Fair Value Analysis", "summary": "This article provides a valuation analysis of Ensysce Biosciences Inc (ENSC), highlighting its current valuation score, P/E ratio, and industry ranking. As of June 26, 2026, the company holds a valuation score of 9.51, placing it 27th out of 387 in the Biotechnology & Medical Res", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-ensc/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-22T23:10:42", "published_display": "22 Jun 2026 23:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ensysce Biosciences Inc (ENSC) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "This article provides an overview of Ensysce Biosciences Inc (ENSC) stock information, including its dividend history and stock split events. It indicates that the company has distributed no dividends over the past five years but has undergone several merger-related stock splits ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-ensc/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-19T01:49:01", "published_display": "19 Jun 2026 01:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ensysce Biosciences Inc (ENSC) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "This article from TradingKey provides a revenue breakdown for Ensysce Biosciences Inc (ENSC). It states that relevant data regarding the company's business segments, regional revenue, and profit contribution have not yet been disclosed by the company. The page also presents basic", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-ensc/revenue", "source_name": "TradingKey", "published_at": "2026-06-19T00:49:01", "published_display": "19 Jun 2026 00:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ensysce Biosciences Inc (ENSC) Financial Health: Profitability & Balance Sheet Analysis", "summary": "Ensysce Biosciences Inc (ENSC) has a weak financial health score of 7.50 out of 388 in the Biotechnology & Medical Research industry, with average operating efficiency. The company's latest quarterly revenue decreased by 27.18% year-over-year, and its net profit saw an 82.80% yea", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-ensc/financial-health", "source_name": "TradingKey", "published_at": "2026-06-18T11:09:32", "published_display": "18 Jun 2026 11:09", "sentiment": "negative", "sentiment_pct": 30, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ensysce Biosciences Inc (ENSC) Institutional Confidence", "summary": "This article provides an \"Institutional Confidence\" score for Ensysce Biosciences Inc (ENSC) as of June 17, 2026, which remains unchanged at 3.00. It details the shareholdings and activity of several institutional investors, including Adage Capital Management, L.P. and DRW Securi", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-ensc/sentiment", "source_name": "TradingKey", "published_at": "2026-06-18T10:09:32", "published_display": "18 Jun 2026 10:09", "sentiment": "positive", "sentiment_pct": 69, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ensysce Biosciences Inc (ENSC) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "This article provides a technical analysis of Ensysce Biosciences Inc (ENSC), detailing its current price momentum score, support and resistance levels, and insights from various technical indicators. It notes ENSC's stock is trading between resistance at $0.32 and support at $0.", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-ensc/technical", "source_name": "TradingKey", "published_at": "2026-06-18T10:09:32", "published_display": "18 Jun 2026 10:09", "sentiment": "negative", "sentiment_pct": 38, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ENSC Stock Chart | ENSYSCE BIOSCIENCES INC (NASDAQ:ENSC)", "summary": "This page from ChartMill.com provides a stock chart and current price information for ENSYSCE BIOSCIENCES INC (NASDAQ:ENSC). It shows the stock's performance, including daily, weekly, and monthly views, along with technical and fundamental analysis options. The current stock pric", "url": "https://www.chartmill.com/stock/quote/ENSC/stock-chart", "source_name": "ChartMill", "published_at": "2026-06-06T02:09:24", "published_display": "06 Jun 2026 02:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ENSC - Ensysce Biosciences Inc Stock Price and Quote", "summary": "This page provides a detailed overview of Ensysce Biosciences Inc (ENSC) stock, including its latest trading information, financial metrics, and a comprehensive list of recent news and press releases. It highlights the company's focus on developing tamper-proof opioids with overd", "url": "https://finviz.com/stock?t=ENSC", "source_name": "Finviz", "published_at": "2026-06-05T01:09:41", "published_display": "05 Jun 2026 01:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ensysce Biosciences Files for Sale of 1.3 Million Shares", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/ensysce-biosciences-files-sale-1-210241213.html", "source_name": "MT Newswires", "published_at": "2026-06-04T21:02:41+00:00", "published_display": "04 Jun 2026 21:02", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ensysce Biosciences (NASDAQ: ENSC) registers up to 1.3M shares for resale", "summary": "Ensysce Biosciences (NASDAQ: ENSC) has filed an S-3 registration statement to register up to 1.3 million shares of common stock for resale. These shares are primarily issuable to a manufacturing counterparty and through a separate agreement, with proceeds from resales going to th", "url": "https://www.stocktitan.net/sec-filings/ENSC/s-3-ensysce-biosciences-inc-shelf-registration-statement-fbc343994331.html", "source_name": "Stock Titan", "published_at": "2026-06-04T20:38:40", "published_display": "04 Jun 2026 20:38", "sentiment": "negative", "sentiment_pct": 37, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ensysce Biosciences receives Nasdaq notice for non-compliance with equity rule", "summary": "Ensysce Biosciences (NASDAQ: ENSC) has received a notice from Nasdaq for non-compliance with the minimum stockholders' equity requirement, falling below the $2.5 million threshold as of March 31, 2026. The company must submit a plan to regain compliance within 45 days to avoid de", "url": "https://www.investing.com/news/sec-filings/ensysce-biosciences-receives-nasdaq-notice-for-noncompliance-with-equity-rule-93CH-4707811", "source_name": "Investing.com", "published_at": "2026-05-22T23:39:52", "published_display": "22 May 2026 23:39", "sentiment": "negative", "sentiment_pct": 20, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ensysce Biosciences (NASDAQ: ENSC) warned on Nasdaq equity listing rule", "summary": "Ensysce Biosciences Inc. (NASDAQ: ENSC) has received a notice from Nasdaq regarding its non-compliance with the minimum $2.5 million stockholders\u2019 equity requirement as of March 31, 2026. The company has 45 days, until July 6, 2026, to submit a plan to regain compliance, with a p", "url": "https://www.stocktitan.net/sec-filings/ENSC/8-k-ensysce-biosciences-inc-reports-material-event-c5cdb7224555.html", "source_name": "Stock Titan", "published_at": "2026-05-22T20:39:52", "published_display": "22 May 2026 20:39", "sentiment": "negative", "sentiment_pct": 19, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ensysce Biosciences Reports First Quarter 2026 Financial Results", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/ensysce-biosciences-reports-first-quarter-201500674.html", "source_name": "ACCESS Newswire", "published_at": "2026-05-15T20:15:00+00:00", "published_display": "15 May 2026 20:15", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ensysce CEO outlines abuse-resistant opioid approach in Amsterdam", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxQeTN6dXYzUFJLSUQ3X1JTdzdRbFFQUmNIMEpCNzhYeHgtczVRLUpzdlc0eVlYLUdRYkxBUXRmWXJEakM2RUZ5X0tXMkF0dnF5ZUR6QWxsc3pFdk5oV2FXcnBxZ0F6SEFobmFhY1EwanE4cHR6cHQ4ZjZBS0hJRmROWWNialRLZmwxcWVka0doZTJLNnpBQ0U5c1ZEV2IxMDNBY0t3Q1pVUjlFbjNTWEV0RGxOcVc?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-08T07:00:00+00:00", "published_display": "08 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CEO takes live questions on Ensysce PF614 pain-drug plans", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxPbnRVX3pjX2NOLXFTdFVzVkM1Zl82Z2VVdmxEV1FsT0JUMTRVUTBEdTE1VUJ3TU9fSlQwa1Rfb1pOZm1uOVZXa3d1dU5YekMxVWxYbXFFS01ncG11U0FydzBjU0ZGbHY1S3JPRlJ2cjlvZm9RTF9JWWdXMXg0ZHNON2c4N3o1cEdiTzJIcnlObHdxMlhSOWNBbkhxczNTMTI4bnVQTFR4SEZ6ZW1teWdmTmNuZ0RIMVlN?oc=5", "source_name": "Stock Titan", "published_at": "2026-03-04T08:00:00+00:00", "published_display": "04 Mar 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Opioid safety drug developer Ensysce explores deals, possible asset sales", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxPNW9ZTzYwck1aTndlYjJYbEctQkdDRXowblhRUnU1S0piNmFzQ3hmSldkRExtNGNSdlB3bF9qUXlIUnh0RmRsc0NhbUtfWkotbURZY2Jxb1FKN1plNFZvT3U1VHBzNVA1NlFFaHZxS25zSmJjMld1WWtjaDVFRnItNnFESVJWMDZiTVVEbEF4RkFsRFlYa2NzNXU3eWttdzg4TXkxakZqX0FyTHV1dDFESTB4c1RyT2pTMWhHQg?oc=5", "source_name": "Stock Titan", "published_at": "2026-02-25T08:00:00+00:00", "published_display": "25 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Should You Buy Ensysce Biosciences After Share Sale?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiggFBVV95cUxQcFdydHZiQXhMX1Y3aElvVGxRcHNEa3FpNGhpQWJTNC1FTzRVTjhaYUtrcXo5S2lmOTJRWGhQbVNCTk9NU2I4RDRzckl2d3dLQzNEZEcwRFM4TVI5cnVsUS1pUnl0bWtGVmdVcUY2TTlvQXF6aDZ5R2JMVVNyV3kwOGNB?oc=5", "source_name": "StocksToTrade", "published_at": "2025-12-09T08:00:00+00:00", "published_display": "09 Dec 2025 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Ensysce Biosciences a Hidden Gem?", "summary": "", "url": "https://news.google.com/rss/articles/CBMihgFBVV95cUxNMG5pUFM3a0ZlSEk5QWVFaktVWTd1NXpXQjhTazl5RzA0VHl2SGU1VEpScGRjb2NuSUFMTXdjckl2M2ZMdW1uSEhyaElpRVJDVmVET08xekprb21ZbHVYN0Z2VDhJQlotU3I1anJmRFd0WWlzQ2tLUVByMzNjdU56RHpiRzIxZw?oc=5", "source_name": "timothysykes.com", "published_at": "2025-12-09T08:00:00+00:00", "published_display": "09 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ensysce Biosciences Stock Rises On Positive Data From Opioid Overdose Protection Study: Retail\u2019s Thrilled", "summary": "", "url": "https://news.google.com/rss/articles/CBMi3AFBVV95cUxOcXJyVmIxNEsyR0ZuTjdvYmRHWFhLQkJnZllQQjdlOHR0OFgyNmJuTWJ5SzZFZjdfSnVxcFpfTGkxdXNmaGNqMURnTjhFSWtiNTJZc0drOVp2LXpqLXJfcjRzdVBwUTk1Qjl3dThrZTFxT2hLeVVVT29ETUJnZTJQTklTbkRxZ2NXdFFrN1pKbDBkenA2ZjlueVBFWmpxZzJOUnI2ekY3eVc2c3pYdXUwaE90YjI2MWtEMHB1S2ZqUlJhbDRCMEIycTJDa0JlWnZjZ0wzRFBRd1BhdWxm?oc=5", "source_name": "Stocktwits", "published_at": "2025-04-15T07:00:00+00:00", "published_display": "15 Apr 2025 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ensysce Biosciences Stock Price Forecast. Should You Buy ENSC?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiSEFVX3lxTE1FZWo2N3QxWXRETHA0SFhYMXA3R1JYT1A1OERMbC1BNk5WWnl2UVF3VEdOTnNBVU1aMDdVdVBYaHp1VHZsSExLRA?oc=5", "source_name": "StockInvest.us", "published_at": "2021-07-16T13:58:03+00:00", "published_display": "16 Jul 2021 13:58", "sentiment": "positive", "sentiment_pct": 66, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ensysce Biosciences (ENSC) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiWkFVX3lxTE9ueEhTdmx2aGpyRms0X0NJZDRlTG50Y3UzQURZYk80amtMSlRpSkdnUFBxbkRsaHhHS3ZybU5Cd0ZVbHNYTnlKSjdVbGxNOHFPSzlqN0hXV2Npdw?oc=5", "source_name": "MarketBeat", "published_at": "2021-07-06T10:17:51+00:00", "published_display": "06 Jul 2021 10:17", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T07:00:00+00:00", "published_display": "13 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 97, "total_relevant": 53, "sentiment_summary": {"positive": 12, "negative": 8, "neutral": 33, "score": 52, "total": 53, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 84, "events": [{"event": "general", "label": "Market update", "weight": 19.25, "count": 35}, {"event": "earnings", "label": "Earnings", "weight": 6.46, "count": 14}, {"event": "analyst", "label": "Analyst action", "weight": 0.55, "count": 1}, {"event": "liquidity", "label": "Balance sheet", "weight": 0.55, "count": 1}, {"event": "deals", "label": "Deals and strategy", "weight": 0.55, "count": 1}, {"event": "guidance", "label": "Guidance", "weight": 0.55, "count": 1}], "positive_events": 12, "negative_events": 8}, "market_context": {"has_market_context": true, "latest_close": 0.28, "latest_week": "2026-07-17", "one_week_move": 4.8, "four_week_move": 4.2, "twelve_week_move": -31.7, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": 0.960556, "market_dynamics_buy_signal": false, "relative_strength": -78.635101, "fair_value_gap": -96.1, "fair_value_label": "Below fair value", "fair_value_tone": "positive", "expectation_direction": "negative", "expectation_probability": 36.2229, "reaction_label": "Price confirming higher", "reaction_tone": "positive", "market_sentence": "+4.8% over one week, +4.2% over four weeks, trend inactive, and below fair value."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "positive", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 62, "badges": ["Value support"], "opportunities": ["Price is below fair value while news tone is not negative."], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Stock Titan", "count": 10}, {"label": "Market source", "count": 7}, {"label": "TradingView", "count": 6}, {"label": "TradingKey", "count": 6}, {"label": "Investing.com", "count": 3}, {"label": "ChartMill", "count": 2}, {"label": "MT Newswires", "count": 2}, {"label": "simplywall.st", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 44}, {"label": "Industry context", "count": 9}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 35}, {"label": "Earnings", "count": 14}, {"label": "Analyst action", "count": 1}, {"label": "Balance sheet", "count": 1}, {"label": "Deals and strategy", "count": 1}, {"label": "Guidance", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "52/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "positive", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "84/100 classification confidence."}, {"label": "Company focus", "value": "44", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "0", "tone": "neutral", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "+4.8% over one week, +4.2% over four weeks, trend inactive, and below fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Ensysce Biosciences (ENSC) price target decreased by 34.79% to 16.78"}], "updated_at": "2026-07-22T02:20:35.166962+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}